Cargando…

Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review

PURPOSE: A systematic literature review was conducted to assess the use of home injections (self/partner/healthcare provider [HCP]-administered) of somatostatin analogs (SSAs) as an alternative to healthcare-setting injections in patients with acromegaly and neuroendocrine tumors (NETs). METHODS: ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boguszewski, Cesar L., Korbonits, Márta, Artignan, Audrey, García, Almudena Martín, Houchard, Aude, Ribeiro-Oliveira, Antonio, de Herder, Wouter W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651885/ https://www.ncbi.nlm.nih.gov/pubmed/36369434 http://dx.doi.org/10.1007/s12020-022-03227-0

Ejemplares similares

PMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey
por: Ribeiro-Oliveira, Antonio, et al.
Publicado: (2022)

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
por: O’Toole, Dermot, et al.
Publicado: (2022)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
por: Adelman, Daphne T, et al.
Publicado: (2012)

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
por: Strasburger, Christian J, et al.
Publicado: (2016)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands
por: Gadelha, Monica R, et al.
Publicado: (2023)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

Case report: A particularly rare case of endogenous hyperinsulinemic hypoglycemia complicated with pregnancy treated with short-acting somatostatin analog injections
por: Barsi, Ádám, et al.
Publicado: (2022)

Antiproliferative effects of somatostatin analogs in endocrine tumours
por: Zatelli, Maria Chiara
Publicado: (2009)

A review of the use of somatostatin analogs in oncology
por: Keskin, Ozge, et al.
Publicado: (2013)

Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog
por: Costa, Ricardo, et al.
Publicado: (2013)

Somatostatin analogs: is one better than other?
por: Rossana, Berardi, et al.
Publicado: (2017)

The Coordination Abilities of New Cyclic Analogs of Somatostatin
por: Marciniak, Aleksandra, et al.
Publicado: (2016)

Somatostatin Analogs in Clinical Practice: A Review
por: Gomes-Porras, Mariana, et al.
Publicado: (2020)

The Management of Persistent or Recurrent Variceal Bleeding After Injection Sclerotherapy by Somatostatin
por: Jenkins, S. A., et al.
Publicado: (1992)

Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
por: Rossi, Valentina, et al.
Publicado: (2019)

Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review
por: Morland, David, et al.
Publicado: (2023)

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
por: Eychenne, Romain, et al.
Publicado: (2020)

Insights into Structure-Activity Relationships of Somatostatin Analogs Containing Mesitylalanine
por: Martín-Gago, Pablo, et al.
Publicado: (2013)

A case of malignant insulinoma responsive to somatostatin analogs treatment
por: Caliri, Mariasmeralda, et al.
Publicado: (2018)

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
por: Fani, Melpomeni, et al.
Publicado: (2022)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas
por: Wang, Ji-wen, et al.
Publicado: (2014)

Somatostatin Analogs in the Medical Management of Occult Bleeding of the Lower Digestive Tract
por: Martin-Grace, Julie, et al.
Publicado: (2015)

A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs
por: Crespo-Jara, Aurora, et al.
Publicado: (2016)

Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma
por: Periferakis, Argyrios, et al.
Publicado: (2021)

Managing Seroma Formation Post Breast Surgery through Somatostatin Analogs
por: Nagayama, Aiko, et al.
Publicado: (2023)

Evaluation of a New (177)Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5
por: Mansi, Rosalba, et al.
Publicado: (2020)

Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs
por: Yuen, Kevin C. J., et al.
Publicado: (2021)

Safety engineered injection devices for intramuscular, subcutaneous and intradermal injections in healthcare delivery settings: a systematic review and meta-analysis
por: Harb, Alain C., et al.
Publicado: (2015)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
por: Cella, David, et al.
Publicado: (2021)

Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
por: Fernandes, Isabel, et al.
Publicado: (2012)

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Somatostatin analog challenge test in the pre-surgical management of ACTH-secreting pheochromocytoma
por: Rossini, Alessandro, et al.
Publicado: (2019)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sr2knuntc2dasvvme9b25qua6m